학술논문
Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15698041